医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pharmaron Receives a CFDA GLP Certificate for its Safety Assessment Facility

2015年12月16日 AM05:51
このエントリーをはてなブックマークに追加


 

BEIJING

Pharmaron announced today that the company has received a Certificate of GLP Compliance, covering genetic toxicology and reproductive toxicology (DART Segments I and II), from the Chinese Food and Drug Administration (CFDA) for its GLP safety assessment facility in Beijing. This is the second GLP compliance certificate granted to this facility by the CFDA since 2013. As such, Pharmaron can offer full IND-enabling safety assessment services to partners in support of their IND filings with the CFDA.

Dr. Boliang Lou, Pharmaron Chairman and CEO, commented, “this certificate is another testimony of our determination for our safety assessment facility to be fully compliant with the CFDA GLP guidelines and a reflection of the CFDA’s continued confidence in our quality. Our customers once again can be assured of the high quality of our safety assessment services. Integrated with other already established platforms including DMPK, pharmacology and CMC at Pharmaron, this further strengthens our leading position in providing integrated preclinical services, including those required for IND filing with the CFDA, for biopharmaceutical and biotech companies in China and throughout the world, to facilitate the development of safer drugs for patients.”

Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and safety assessment to chemical & pharmaceutical development. Its safety assessment platform has a long-standing track record of performing studies for international IND/NDA filing, particularly with the US FDA. With the addition of the CFDA-granted GLP compliance certificates since 2013, Pharmaron is in a leading position in providing IND/NDA-enabling services for multiple regulatory filings, including the CFDA, US FDA and OECD regulatory agencies. For more information, please visit www.pharmaron.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151215006757/en/

CONTACT

Pharmaron
Katherine Lee
Senior Vice President of Strategic
Partnerships
562-686-9786
klee@pharmaron.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田获得CHMP肯定意见,接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者
  • 富士制药向Alvotech投资5000万美元
  • 武田薬品、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者を治療するためのアドセトリス(ブレンツキシマブ・ベドチン)とAVDの併用に関するCHMPの肯定的見解を受領
  • AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
  • Aptorum Group [APM] to Ring the NASDAQ Stock Market Closing Bell in Celebration of IPO Closing